 The study is now underway at Alfred Hospital in Melbourne and is being led by principal researcher Jason Lickliter , MD, Chief Medical Officer of Nucleus Network, Australias largest and most experienced Phase 1 clinical research organization. The initiation of this Phase 1 in-human safety and tolerability clinical study of ultra-micronized formulation of PEA is a ground-breaking milestone for our company as we stride forward to find novel anti-inflammatory treatment outcomes for patients by targeting the CB2 receptors of the endocannabinoid system, said Raza Bokhari , MD, Executive Co-Chairman CEO. 